

2024

Clinical outcomes in high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus non-switchers: Results from a PV-switch study

Koschmieder S, Schulte C, von der Heyde E, Busque L, Boyer-Perrard F, Devos T, Passamonti F, Cheng WY, Cheng M, Nuortti M, Baum V, Harrison C

In preparation

Final results from a large, non-interventional phase 4 study of ruxolitinib for the treatment of myelofibrosis in clinical routine

Koschmieder S, Isfort S, Schulte C, Jacobasch L, Geer T, Hansen R, Reiser M, Koenigsmann M, Heinrich B, Wehmeyer J, von der Heyde E, Tesch H, Gröschl B, Bachhuber P, Großer S, Koehler M, Pahl HL

J Hematol 2024, in preparation

Intraindividual comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment and its impact on survival – an analysis by the German study group for MPN (GSG MPN)

Manz K, Heidel FH, Koschmieder S, Schlag R, Lipke J, Stegelmann F, Griesshammer M, Klausmann M, Crodel C, Hochhaus A, Schulz H, Göthert JR, Al-Ali H, Becker H, Reiter A, Beutel G, Kricheldorf K, Brümmendorf TH, Hoffmann W, Döhner K, Isfort S

Abstract, ASH Dec 7 – Dec 10 2024, San Diego, California, in preparation

Real-world experience with Isatuximab in patients with relapsed and/or refractory Multiple Myeloma (RMM): Second interim analysis

Martin T, Gaballa M ... Schulte C et al.

Abstract, ASH Dec 7 – Dec 10 2024, San Diego, California, in preparation

Real-world treatment patterns and clinical outcomes in locally advanced or metastatic urothelial carcinoma in Germany: retrospective CONVINCE study

Schlack K, Machtens S, Kubin T, Ruhnke M, Schulte C, Eisen A, Osowski U, Guenther S, Kearny M, Lipp R, Schmitz S

The Oncologist, submitted

First-line Venetoclax combinations versus chemoimmunotherapy in fir patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicenter, open-label, randomized, phase 3 trial

Fürstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindström V, Juliusson G, Janssens A, Levin M-D, da Cunha-Bang C, Schneider C, Goldschmidt N ... Schulte C et al

The Lancet Oncology Vol 25 (6), June 2024, 744-759

Patients with multiple myeloma – what happens in second line after first—line Lenalidomide? Data from the German Mariam Registry

Reiser M, Behlendorf T, Bürkle D, Lipke J, Schlag R, Tech S, Medinger T, Jänicke M, Dechow T, Einsele H, Engelhardt M, Knauf W, Marschner P

Abstract 2937 und Poster P909, EHA Jun 13 – Jun 16 2024, Madrid

Split-dose cisplatin plus gemcitabine use and associated clinical outcomes in the first-line (1L) treatment of locally advanced or metastatic urothelial cancer (la/mUC): Results of a retrospective observational study in Germany (CONVINVE)

Schlack K, Kubin T, Ruhnke M, Schulte C, Machtens S, Eisen A, Osowski U, Guentehr S, Kearney M, Lipp R, Schmitz R

DKK 2024 Congress 21 Feb – 24 Feb 2024, Berlin

Real-world treatment patterns and clinical outcomes in locally advanced or metastatic urothelial carcinoma in Germany: retrospective CONVINCE study

Schlack K, Machtens S, Kubin T, Ruhnke M, Schulte C, Eisen A, Osowski U, Guenther S, Kearny M, Lipp R, Schmitz S

Abstract 551, ASCO Jan 25 – Jan 27 2024, San Francisco, California

2023

Routine care of patients with resectable gastric (GC) and gastroesophageal junction (GEJC) adenocarcinoma – Data of the retrospective perioperative cohort of the registry platform

Lordick F, dechow T, von der Heyde E, Sadjadian P, Schulte C, de Buhr R, Lennartz C, Binnering A, Jänicke M, Lorenzen S, Reinacher-Schick A, Potthoff K

Abstract, Jahrestagung DGHO Oct 13 – Oct 16 2023, Hamburg

Routine care of patients with multiple myeloma who received treatment in fourth or higher line between 09/2020 and 05/2023

Weide R, Karbe C, Lipke J, Verpoort K, Karcher A, Hensel M, Linde H, Schnell R, Mohm J, Vehling-Kaiser U, Braun U, Tamm I, Rothe A, Otremba B, Kropff M, Jacobs G, Chemnitz JM, Nusch A, von der Heyde E, Feiten S

Abstract, Jahrestagung DGHO Oct 13 – Oct 16 2023, Hamburg

Treatment results of chronic lymphatic leukemia (CLL) 2019-2022 in oncology group practices in Germany

Weide R, Lipke J, Karcher A, Schnell R, Vehling-Kaiser U, Tamm I, Mohm J, Feiten S

Abstract, Jahrestagung DGHO Oct 13 – Oct 16 2023, Hamburg

Applicability of the new WHO classification for the MDN: Data from the Düsseldorf MDS registry

Nachtkamp K, Vukelja M, Strupp C, Kasprzak A, Baldus S, Rudelius M, Aul C, Pfeilstöcker M, Valent P, Hofmann W, Schütte J, Blum S, Haase D, Krieger O, Lübbert M, Stauder R, Schlenk R, Götze K, Lipke J, Beier F, Giagounidis A, Dietrich S, Hildebrandt B, Betz B, Gattermann N, Germing U

Poster, Jahrestagung DGHO Oct 13 – Oct 16 2023, Hamburg

Systemic treatment of cholangiocellular carcinoma in Germany – Results from the prospective national intersectoral cohort study JADE

Freiberg-Richter J, Uhlig J, von der Heyde E, Schröder J, Pereira P, Hofmann WP, Schuler MK, Zingerle M, Nusch A, Ketzler-Henkel S, Siebenbach HU, Weinberg F, Bengsch F, Jänicke M, Potthoff K, Berg T, Galle P, Thimme R

Abstract, Jahrestagung DGHO Oct 13 – Oct 16 2023, Hamburg

Influence of different therapy strategies in MDS on overall survival with regard to different decades: Data from the German MDS-Registry

Welsch J, Aul C, Goetze K, Kasprzak A, Schulz FI, Strupp C, Germing U, Kobbe, Nachtkamp K, Lipke J, Dietrich S, Parmentier S

Lecture, Jahrestagung DGHO Oct 13 – Oct 16 2023, Hamburg

Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKOMO non-interventional phase IV trial

Koschmieder S, Isfort S, Schulte C, Jacobasch L, Geer T, Reiser M, Koenigsmann M, Heinrich B, Wehmeyer J, von der Heyde E, Tesch H, Gröschl B, Bachhuber P, Großer S, Pahl HL

Ann Hematol: Published: Oct 4, 2023, DOI: <https://doi.org/10.1007/s00277-023-05458-1>

Real-world analysis of ruxolitinib in myelofibrosis: interim result of the JAK inhibitor-naïve patients treated within the JAKOMO non-interventional phase IV trial

Koschmieder S, Isfort S, Schulte C, Jacobasch L, Geer T, Hansen R, Reiser M, Klausmann M, Koenigsmann M, Wehmeyer J, Heinrich B, Gröschl B, Bachhuber P, Großer S, Pahl HL

Ann Hematol: Published: Oct 4 2023 DOI: 10.1007/s00277-023-05458-1

Real-world experience with Isatuximab in patients with relapsed and/or refractory multiple myeloma (RRMM): IONA-MM first interim analysis

Wehrhan T, Schulte C, Fries S, Kröning H, Martin T, Beksac M, Cavo M, Tsukada N, Tekle C, Zhao Z, Manasanch EE, Knauf W

Poster, Jahrestagung DGHO Oct 13 – Oct 16 2023, Hamburg

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Fürstenau M, Ritgen M, Robrecht S, von Tresckow J, Zhang C, Schilhabel A, Gregor M, Thornton P, Staber PB, Tadmor T, Janssens A, Levon MD, Da Cunha-Bang C, Schneider C ... Schulte C et al.

Blood (2023) 142 (Supplement 1): 635, doi.org/10.1182/blood-2023-173709

Abstract, ASH 09 Dec – 12 Dec 2023, San Diego, California

Targeted agents in chronic lymphocytic leukemia (CLL): Data on outcomes and subsequent therapies of patients observed within the German CLL Study Group (GCLLSG) registry

Kutsch N, Ligtvoet R, Robrecht S, Linde H, Illmer T, Dörfel S, Lipke J, Aldaoud A, Schlag R, Dengler J, Al-Sawaf O, Langerbeins P, Cramer P, Eichhorst B, Hallek M, Fischer K, Fink AM

Abstract 1212 und Poster, iwCLL 07 Oct – 09 Oct 2023, Boston, Massachusetts

Iron chelation in patients with myeloplastic syndromes and myeloproliferative neoplasms – Real-world data from the German non-interventional study EXCALIBUR

Schulz F, Hauch U, Ketzler-Henkel S, Von der Heyde E, Koertigmann M, Lauseker M, Schulte N, Germing U

Preprints.org, posted 20 Sep 2023, doi: 10.20944/preprints202309.1338.v1

Time to transfusion dependency after diagnosis of myelodysplastic neoplasia (MDS) is another prognostic factor in low/intermediate-risk patients

Steinmetz T, Toczek-Thiel J, Lipke J, Liersch R, Sauer A, Tesch H, Heßling J, Totzke U, Schmitz S

Leukemia and Lymphoma: Published: Jul – Aug 2023, Epub: May 31, 2023

doi: 10.1080/10428194.2023.2214649

Dissecting the genetic heterogeneity of gastric cancer

Hess T, Maj C, Gehlen J, Borisov O, Haas SL, Gockel I, Vieth M, Piessen G, Alakus H, Vashist Y, Pareira C, Knapp M ... Ludwig M et al

The Lancet Vol 92, June 2023

eBioMedicine 2023 Jun;92:104616, doi: 10.1016/j.ebiom.2023.104616. Epub 2023 May 18.

Dissecting the genetic heterogeneity of gastric cancer

Hess T, Maj C, Gehlen J, Borisov O, Ludwig M, Schumacher J et al.

eBiomedicine: Published: May 18 2023, DOI: <https://doi.org/10.1016/j.ebiom.2023.10461>

Time to first transfusion in lower-risk patients with myelodysplastic neoplasia (MDS) is another prognostic factor of survival

Steinmetz HT, Toczek-Thiel J, Lipke J, Liersch R, Sauer A, Tesch H, Heßling J, Totzke U, Schmitz S

Leukemia and Lymphoma 2023 Vol 64 No. 8, 1476 – 1479, doi.org/10.1080/10428194.2023.2214649

Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany

Kröning H, Göhler T, Decker T, Grundeis M, Kojouharoff G, Lipke J, Semsek D, Moorahrned E, Sauer A, Bruch H-R, Liersch R, Nusch A, Vehling-Kaiser U, Welslau M, Grunewald R, Harich H-D, Staphany M, Uhlig J, de Buhr R, Frank M, Hogrefe C, Marschner N, Potthoff K, Hartmann F, Reisländer T, Schwaner I

Int J Cancer 2023;153:1227-1240

Drug-monitoring detects under- and overdosing in patients receiving 5-fluoruracil containing chemotherapy – results of a prospective, multicenter German observational study

Li M, Mindt S, Lück A, Hutzschenreuter U, Kollendt M, Lathan B, Zöller T, Frank-Gleich S, Lorentz C, Lamberti C, Sick C, Zingerle M, Tesch H, Stein W, Hebart H, Stosiek C, Sandner R, Fries S, Burkholder I, Hofheinz R-D

ESMO Open: Published: March 23, 2023 , DOI: 10.1016/j.esmoop.2023.101201

Split-dose cisplatin plus gemcitabine use and associated clinical outcomes in the first-line (1L) treatment of locally advanced or metastatic urothelial cancer (la/mUC): Results of a retrospective observational study in Germany (CONVINVE)

Schlack K, Kubin T, Ruhnke M, Schulte C, Machtens S, Eisen A, Osowski U, Guentehr S, Kearney M, Lipp R, Schmitz R

Abstract und Poster 2388P, ESMO Oct 20 – Oct 24 2023

2022

Real-world burden of peripheral neuropathy in patients with multiple myeloma in Germany

Ketzler-Henkel S, Stolpe T, Ertel F, Knapp R, Flossmann C

Poster P 984, Jahrestagung DGHO Oct 7 – Oct 10 2022, Wien

Abstract, Jahrestagung DGHO Oct 7 – Oct 10 2022, Wien

Treatment sequences in patients with chronic lymphocytic leukemia (CLL): an analysis of the German CLL Study Group (GCLLSG) registry

Illmer T, Lipke J, Schlag R, Dengler J, Kutsch N, Stumpf J, Giza A, Robrecht S, Eichhorst B, Fischer K, Hallek M et al.

Abstract, Vortrag V41, Jahrestagung DGHO Oct 7 – Oct 10 2022, Wien

Effectiveness, safety and QoL of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the non-interventional TACTIC study in Germany

Kröning H, Göhler T, Decker T, Grundeis M, Kojouharoff G, Lipke J, Semsek D, Moorahrend E, Sauer A, Bruch H-R, Liersch R, Nusch A, Vehling-Kaiser U, Welslau M, Grunewald R, Harich H-D et al.

International Journal of Cancer, IJC-22-2842 2022; Published: 2023 Sep 15, Epub 2023 Jun 1.

DOI: 10.1002/ijc.34603.

Final quality of life results of the non-interventional study TACTIC Trifluridine/Tipiracil in patients with metastatic colorectal cancer in clinical routine in Germany

Schwane I, Kröning H, Göhler T, Decker T, Grundeis M, Kojouharoff G, Lipke J, Semsek D, Moorahrend E, Sauer A, Bruch H-R, Liersch R, Nusch A, Vehling-Kaiser U, Welslau M, Grunewald R, Harich H-D et al.

Poster P 1006, Jahrestagung DGHO Oct 7 – Oct 10 2022, Wien

Treatment sequences in patients with chronic lymphocytic leukemia (CLL): an analysis of the German CLL Study Group (GCLLSG) registry

Kutsch N, Stumpf J, Giza A, Robrecht S, Linde H, Illmer T, Dörfel S, Lipke J, Aldaoud A, Schlag R, Dengler J, Klausmann M, Fischer K, Eichhorst B, Hallek M, Fink AM

Abstract, Jahrestagung DGHO Oct 7 – Oct 10 2022, Wien

The regular care MDS-registry in Germany: First data from the final analysis

Steinmetz HT, Heinz M, Schulte C, Sauer A, Liersch R, Tesch H, Moorahrend E, Heßling J, Reiser M, Schmitz S

Abstract, Jahrestagung DGHO Oct 7 – Oct 10 2022, Wien

Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): Real-world evidence of NSCLC patients treated with radiochemotherapy in Germany – AIO-TRK-0315

Griesinger F, Eberhardt W, Nusch A, Reiser M, Zahn MO, Maintz C, Bernhardt C, Losem C, Stenzinger A, Heukamp LC, Büttner R, Marschner N, Jänicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, Weichert W, Heilmann M, Sadjadian P, Gleiber W, Grah C, Waller CF, Reck M, Rittmeyer A, Christopoulos P, Sebastian M, Thomas M; CRISP Registry Group

Abstract, Jahrestagung DGHO Oct 7 – Oct 10 2022, Wien

Poster, ESMO World Congress on Gastrointestinal Cancer Sep 9 – Sep 13 2022, Paris

Efficacy and safety data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: real-world data from the non-interventional TACTIC study

Kröning H, Göhler T, Decker T, Grundeis M, Koujouharoff G, Lipke J, Semsek D, Moorahrend E, Sauer A, Hartmann F, Reisländer T, de Buhr R, Frank M, Hogrefe C, Marschner N, Potthoff K, Schaner I on behalf of the TACTIC Group

Poster, ESMO World Congress on Gastrointestinal Cancer Sep 9 – Sep 13 2022, Paris

Prognostic characteristics of patients with MDS with aberrations of chromosome 5. Data from the Düsseldorf MDS registry

Schulz F, Kostova J, Hildebrandt B, Nachtkamp K, Strupp C, Gattermann N, Lübbert M, Blum S, Parmentier S, Götze K, Lipke J, Beier F, Hofmann WK, Germing U

Abstract EHA-2183, EHA Jun 9 – Jun 12 2022, München

Causes of mortality in elderly UICC stage III colon cancer (CC) patients – Tumor-related death and competing risks from the German AIO colorectal study group Colopredict Plus (CPP) registry

Nöpel-Dünnebacke S, Jütte H, Denz R, Feder IS, Kraeft aL, Lugnier C, Teschendorf C, Collette D, Böhner H, Engel L, Mueller L, Hartmann F, Kaiser U, Bruch HR, Hollerbach S, Arnold D, Timmesfeld N, Tannapfel A, Reinacher-Schick A

Cancer Medicine: 2022;11:1735-1744

<http://dx.doi.org/10.1002/cam4.4540>

2021

Characteristics of high-risk polycythemia vera patients with suboptimal response to first-line therapy who switched to Ruxolitinib vs those who did not switch: Findings from PV-switch, a multinational, retrospective chart review study

Koschmieder S, Schulte C, von der Heyde E, Busque L, Boyer-Perrard F, Devos T, Passamonti F, Zuurman MW, Paley C, Gilotti G, Cheng WY, Gao C, Cheng M, Wu M, Sheng Duh M, Harrison C

Poster3646, ASH Dec 11- Dec 14 2021, Atlanta, GA

<https://bit.ly/Koschmieder3646?r=qr>

Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia

Fürstenau M, Giza A, Stumpf T, Robrecht S, Maurer C, Linde H, Jacobasch L, Dörfel S, Lipke J, Aldaoud A, Fischer K, Eichhorst B, Hallek M, Fink AM

Am J Hematol 2021 Dec 1;96(12):E457-E460

doi: 10.1002/ajh.26363. Epub 2021 Oct 8

Treatment-free remission in real-world chronic myeloid leukemia patients: Insights from German hematology practices

Dengler J, Tesch H, Jentsch-Ullrich K, Gerhardt A, Schulte C, Lipke J, Löwe G, Kiani A

Karger Verlag Basel, Schweiz; Acta Haematologica 2021-9-23

RAS mutant metastatic colorectal cancer – Real world data from more than 1000 patients from the clinical tumor registry colorectal cancer (TKK)

Schnell R, Dörfel S, Bernhardt C, Eggers E, Fruehauf S et al.

Abstract, Jahrestagung DGHO Oct 1 – Oct 4 2021, Berlin

Current treatment of iron overload in medical daily routine: an update from the German observational study EXCALIBUR (CICL670ADE14)

Metz M, Koenigsmann M, Kubasch AS, Ketzler-Henkel S, Spohn C, Hauch U, von der Heyde E, Schick A, Johr C, Germing U

Vortrag V264 und Abstract, Jahrestagung DGHO Oct 1 – Oct 4 2021, Berlin

Hematological improvement of MDS and MPN patients receiving iron chelating therapy in real-world setting: Adhoc analysis from the German observational study EXCALIBUR

Kubasch AS, Koenigsmann M, Metz M, Ketzler-Henkel S, Spohn C, Hauch U, von der Heyde E, Schick A, Johr C, Germing U

Poster ep259 und Abstract, Jahrestagung DGHO Oct 1 – Oct 4 2021, Berlin

Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): First real-world evidence of NSCLC stage II and III in Germany – AIO-TRK-0315

Eberhardt, Passlick, Stuschke, Gröschel, Christopoulos, Reck M, Grah C, Groth A, Hipper A, Chiabudin M, Fleitz A, Jänicke M, Spring L, Christoph D, Bernhardt C, Reiser M, Zahn MO, Sebastian, Griesinger, Thomas

Abstract, Jahrestagung DGHO Oct 1 – Oct 4 2021, Berlin

Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): First real-world evidence of NSCLC stage II and III in Germany – AIO-TRK-0315

Gröschel, Passlick, Stuschke, Christopoulos, Reck M, Grah C, Groth A, Hipper A, Chiabudin M, Fleitz A, Jänicke M, Spring L, Christoph D, Bernhardt C, Reiser M, Zahn MO, Sebastian, Griesinger, Thomas, Eberhardt

Abstract, ESMO World Congress on Gastrointestinal Cancer Sep 16 – Sep 21 2021, webcast

Hämochromatose – eine wichtige, selten frühzeitig gestellte Differentialdiagnose in der Allgemeinmedizin

Golka K, Collette D, Müller JI, Claus M, Niedner H, Römer HC, Butzeck B

Poster #180, 55. Kongress der DEGAM Sep 16 – Sep 18 2021, Lübeck

Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

Griesinger F, Eberhardt W, Nusch A, Reiser M, Zahn MO, Mainz C, Bernhardt C, Losem C, Stenzinger A, Heukamp LC, Büttner R, Marschner N, Jänicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, Weichert W, Heilmann M, Sadjadian P, Gleiber W, Grah C, Waller CF, Reck M, Rittmeyer A, Christopoulos P, Sebastian M, Thomas M; CRISP Registry Group

Lung Cancer 2021 Feb;152:174-184.

2020

Genetic heterogeneity of MET-aberrant NSCLC and its impact on the outcome of immunotherapy

Kron A, Scheffler M, Heydt C, Ruge L, Schaepers C, Eisert AK, Merkelbach-Bruse S, Riedel R, Nogova L, Fischer RN, Michels S, Abdulla DSY, Koleczko S, Fassunke J, Schultheis AM, Kron F, Ueckerath F, Wessling G, Sueptitz J, Beckers F, Braess J, Panse J, Grohe C, Hamm M, Kabitz HJ, Kambartel K, Kaminsky B, Krueger S, Schulte C, Lorenz J, Lorenzen J, Meister W, Myer A, Kappers J, Reinmuth N, Schaaf B, Schulte W, Serke M, Buettner R, Wolf J

Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 16(suppl 3), Dec 2020

DOI:10.1016/j.jtho.2020.11.017

Biomarker testing in non-small cell lung cancer in routine care: analysis of the first 3,717 patients in the German observational, prospective, nation-wide CRISP Registry (AIO-TRK-0315)

Griesinger F, Eberhardt W, Nusch A, Reiser M, Zahn M-O, Maintz C, Bernhardt C, Losem C, Marschner N, Jänicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, Weichert W, Heilmann M, Sadjadian P, Gleiber W, Grah C, Waller C, Reck M, Rittmeyer A, Christopoulos P, Sebastian M, Thomas M

Lung Cancer IF 4.599 2020

doi: 10.1016/j.lungcan.2020.10.012. Epub 2020 Nov 2.

Trifluridine/Tipiracil in patients with refractory metastatic colorectal cancer in clinical routine in Germany: interim results of the non-interventional study TACTIC

Göhler T, Decker T, Grundeis M, Schwaner J, Sauer A, Fichter C, Moorahrend E, Kröning H, Lipke J, Kojouharoff G, Frank M, Hogrefe C, Marschner N, Potthoff K

Abstract, Jahrestagung DGHO Oct 9 – Oct 12 2020, Basel

Changes in treatment of patients with multiple myeloma in Germany – results from the MYRIAM registry

Engelhardt M, Knauf W, Lipke J, Reiser M, Dörfel S, Kortüm M, Schlag R, von der Heyde E, La Rosée P, Pfannes R, Lamberti C, Houet L, Medinger T, Jänicke M, Marschner N

Abstract, Jahrestagung DGHO Oct 9 – Oct 12 2020, Basel

Causes of mortality in elderly UICC stage III colon cancer (CC) patients (pts.) – Tumor related death and competing risks from the Colopredict Plus (CPP) registry

Nöpel-Dünnebacke S, Klaassen-Mielke R, Feder IS, Kraeft AI, Teschendorf C, Collette D, Böhner H, Engel I, Müller I, Hartmann F, Kaiser U, Bruch H, Giaguonidis A, Graeven U, Hollerbach S, Arnold D, Timmesfeld N, Reinacher-Sachick A et al.

Poster #3249, ESMO World Congress on Gastrointestinal Cancer Sep 19 - Sep 21 2020, virtual congress

Dynamics in the choice of treatment for patients with multiple myeloma – results from the MYRIAM registry

Engelhardt M, Knauf W, Lipke J, Reiser M, Dörfel S, Kortüm M, Schlag R, von der Heyde E, La Rosée P, Pfannes R, Lamberti C, Houet L, Medinger T, Jänicke M, Marschner N, Dechow T, Einsele H

EHA Jun 11 – Oct 15 2020, virtual congress

Analysis of Natural Killer cell functions in patients with Hereditary Hemochromatosis

Bönnemann V, Claus M, Butzeck B, Collette D, Bröde P, Golka K, Watzl C

EXCLI Journal 19, 430 – 441, Mar 25 2020, Dortmund

Cytoreductive treatment in “real life” – interim-analysis of 434 polycythemia vera patients in Germany

Crudel C, Jentsch-Ullrich K, Jacobasch L, Kiewe P, Kisro J, Lipke J, Prenninger S, Reiser M, Wunschel R, Hochhaus A, Heidel F

Abstract ID 214 DKK Feb 19 – Feb 22 2020, Bonn

Poster, DKK Feb 19 2020, Bonn

ENLARGE-Lung: Two-Year Follow-up of Real-World Patients with Locally Advanced or Metastatic (Stage IIIB/IV) Squamous and Non-Squamous Non-Small Cell Lung Cancer (NSCLC) from a National, Prospective, Non-Interventional Study (NIS ENLARGE) of Nivolumab after Prior Chemotherapy in Germany

Gröschel A, Schumann C, Gütz S, Schulz H, Müller-Huesmann H, Schulte C, Liersch R, von der Heyde E, Wünsch V, Sebastian M

Poster 472, DKK Feb 14 – Feb 22 2020, Bonn

Dynamics in the choice of treatment for patients with multiple myeloma – results from the MYRIAM project

Engelhardt M, Knauf W, Lipke J, Reiser M, Dörfel S, Kortüm M, Schlag R, von der Heyde E, La Rosee P, Mohren M, Pfannes R, Lamberti C, Houet L, Medinger T, Jänicke M, Marschner N, Dechow T, Einsele H

Abstract V1 2020-01-30, EHA June 2020, Frankfurt

Poster EP994, EHA 11 – 14 June 2020, Frankfurt

Untersuchung von Behandlungsrealität, Wirksamkeit und Erkrankungsverlauf von Patienten mit Multiplem Myelom in Deutschland

Knauf W, Engelhardt M, Losem C, Lipke J, Kasper C, Houet L, Medinger T, Jänicke M, Marschner N, Dechow T, Einsele H

Poster MYRIAM, DKK Feb 19 – Feb 22 2020, Bonn

Cytoreductive treatment in real life – interim-analysis of 1282 polycythemia vera patients in Germany

Crodel CC, Jentsch-Ullrich K, Jacobasch L, Kiewe P, Kisro J, Lipke J, Prenninger SW, Reiser M, Wunschel R, Hochhaus A, Heidel FH

Poster, Universitätsklinikum Jena 2020

2019

Cytoreductive treatment in “real life” – interim-analysis of 434 polycythemia vera patients in Germany

Crodel C, Jentsch-Ullrich K, Jacobasch L, Kiewe P, Kisro J, Lipke J, Prenninger S, Reiser M, Wunschel R, Hochhaus A, Heidel F

Poster ASH Dec 7 – Dec 10 2019, Orlando, USA

Behandlung der Immunthrombozyten (ITP) mit Revolade – Ergebnisse der zweiten Interimsanalyse der deutschen nicht-interventionellen Studie RISA

Meyer O, Kämpfe D, Reiser M, Dörfel S, von der Heyde E, Josting A, Lipke J, Ballerstädt N, Michels K

Abstract Nr. A-1089-0013-00560. DGHO Oct 11 – Oct 14 2019, Berlin

Vortrag Jahrestagung DGHO Oct 11 2019, Berlin

Die Behandlung von Myeloproliferativen Neoplasien (MPN) in Deutschland. Ein Update aus dem MPN-Register der niedergelassenen Hämatologen und Onkologen (NIHO-MPN-Register)

Steinmetz H T, Metzger S, Heinz M, Lipke J, Fries S, Sauer A, Uhlig J, Bürkle D, Schneider-Kappus W, Schmitz S

Poster P365 Jahrestagung DGHO Oct 11 – Oct 14 2019, Berlin

Abstract Nr. A-1089-0012-00272, DGHO Oct 11 – Oct 14 2019, Berlin

MyLife: Gesundheitsbezogene Lebensqualität bei Patienten mit Multiplem Myelom – Erste Daten zur Patientenbefragung bei MYRIAM, der prospektiven, intersektoralen klinischen Registerplattform zu Behandlungsrelität, Wirksamkeit und Erkrankungsverlauf von Patienten mit Multiplem Myelom in Deutschland

Engelhardt M, Knauf W, Lipke J, Zahn M-O, Dörfel S, Bittrich M, Reiser M, Sauer A, Aubele P O, La Rosée P, Houet L, Medinger T, Jänicke M, Marschner N, Dechow T, Einsele H

Poster P713 MYRIAM Jahrestagung DGHO Oct 11 – Oct 14 2019, Berlin

Abstract Nr. A-1089-0015-00182, Jahrestagung DGHO Oct 11 – Oct 14 2019, Berlin

Patient-reported outcomes (PRO) on the use of ruxolitinib in myelofibrosis: data from the JAKoMo phase IV trial

Koschmieder S, Schulte C, Reiser M, Hansen R, Koenigsmann M, Geer T, Gröschl B, Großer S, Koehler M

Abstract A-1089-0012-00051, Jahrestagung DGHO Oct 11 – Oct 14 2019, Berlin

Treatment-free remission in real-world chronic myeloid leukemia patients: insights from German clinical hematology practices

Dengler J, Tesch H, Jentsch-Ullrich K, Gerhardt A, Schulte C, Lipke J Löwe G, Holder I, Kiani A

Poster Jahrestagung DGHO Oct 11 – Oct 2019, Berlin

HemaSphere Journal June 2019 Volume 3 – Issue S1 – p162

Characteristics of patients with Acute Myeloid Leukaemia (AML) diagnosed in regular care: Data from the regular care AML-MDS-registry in Germany

Steinmetz HT, Aludin R, Lipke J, Liersch R, Sauer A, Tesch S, Heßling J, Schmitz S

Abstract und Poster P921, Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

Iron chelation therapy in German MDS patients with chronic iron overload under routine clinical practice (an interim analysis of EXCALIBUR study)

Metz M, Koenigsmann M, Nuckel H, von der Heyde E, Ketzler-Henkel S, Hauch U, Spohn C, Schick A, Johr C, Germing U

Poster Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

Second primary malignancy (SPM) in treated and untreated patients with chronic lymphatic leukemia (CLL): an analysis of the registry of the German CLL Study Group (DCLLSG)

Fürstenau M, Stumpf T, Fink A-M, Robrecht S, Bahlo J, Maurer C, Linde H, Jacobasch L, Dörfel S, Lipke J, Aldaoud A, Fischer K, Eichhorst B, Hallek M

Abstract und Vortrag V91 Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

MyLife: Longitudinal assessment of health-related quality of life in patients with multiple myeloma in Germany – First patient-reported outcomes data from MYRIAM, the prospective, national, intersectoral cohort study for treatment and outcome of myeloma patients

Engelhardt M, Knauf W, Lipke J, Zahn MO, Dörfel S, Bittrich M, Reiser M, Sauer A, Aubele PO, La Rosee P, Houet L, Medinger T, Jänicke M, Marschner N, Dechow T, Einsele H

Lecture Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

Data analysis of the thrombopoietin receptor agonist Eltrombopag efficacy in patients pretreated with corticosteroids – results of the 2nd interim analysis of the non-interventional study RISA

Meyer O, Stauch M, Kämpfe D, Schlag R, Reiser M, Dörfel S, von der Heyde E, Josting A, Lipke J, Ballerstädt N, Michels K

Abstract Nr. A-1089-0013-00560 Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

A phase 2 study of Inebilizumab plus Bendamustine versus Rituximab plus Bendamustine for the treatment of relapsed or refractory chronic lymphocytic leukemia

Spaner D, Araujo C, Andrao M, Zaucha J, Bellam N, Schulte C, Patti C, Cascavilla N, Jourdan E, Panwalkar A, Costello R, Yao NS, Elgeioushi N, Li J, Streicher K, Eck S, Marshall S, Gladstone DE

Leukemia and Lymphoma

Treatment of myeloproliferative neoplasm (MPN) in Germany. Update of the real world data from the office based MPN-registry (NIHO-MPN-registry)

Steinmetz HT, Metzger S, Heinz M, Lipke J, Fries S, Sauer A, Uhlig J, Bürkle D, Schneider-Kappus W, Schmitz S

Abstract, Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

CTC-conform patient self-reported determination of chemotherapy-induced peripheral neuropathy (CIPN) is feasible in daily routine practice

Losem C, Dombrowsky J, Schulte C, Bauer I, Steinmetz T

Abstract, Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

2019 interim analysis of the phase IV study JAKOMO: "Real-world" data on the use of ruxolitinib in myelofibrosis

Koschmieder S, Lechner A, Schulte C, Reiser M, Hansen R, Prange-Krex G, Koenigsmann M, Gröschl B, Großer S, Köhler M

Abstract Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

Patient-reported outcome (PRO) on the use of ruxolitinib (RUX) in myelofibrosis (MF): data from the JAKOMO phase IV trial

Koschmieder S, Schulte C, Reiser M, Koenigsmann M, Geer T, Gröschl B, Großer S, Koehler M

Poster Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

Real world evidence: Interim analysis of efficacy in 628 patients with stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) treated with Nivolumab after prior chemotherapy in a national, prospective, non-interventional study (ENLARGE LUNG)

Abstract Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

Iron chelation therapy in German MDS patients with chronic iron overload under routine clinical practice (An interim analysis of EXCALIBUR study)

Metz M, Koenigsmann M, Nuckel H, von der Heyde E, Ketzler S, Hauch U, Spohn C, Schick A, Johr C, Germing U

Abstract Jahrestagung DGHO Oct 11 - Oct 14 2019, Berlin

IO-Synthesis NSCLC: A pooled analysis of real-world survival outcomes for non-small cell lung cancer patients with nivolumab in France and Germany

Dixmier A, Asselain B, Barlesi F, Debieuvre D, Audigier-Valette C, Gröschel A, Gütz S, Liersch R, Moro-Sibilot D, Müller-Huesmann H, Perol M, Raspaud C, Schulte C, Schulz H, Schumann C, Alla V, Calvet CY, Rothnie KJ, Wunsch V, Martin S

Abstract, ESMO World Congress on Gastrointestinal Cancer Sep 27 - Oct 01 2019, Barcelona

2018

Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project

Marschner N, Trarbach T, Rauh J, Meyer D, Müller-Hagen S, Harde J, Dille S, Kruggel L, Jänicke M, The TMK-Group

Breast Cancer Res Treat. Springer, pp 1-12 2018, Springer Nature Switzerland

<https://link.springer.com/article/10.1007/s10549-019-05197>

Assessment of Iron Chelation Therapy in German Patients With Chronic Iron Overload Under Routine Clinical Practice (EXCALIBUR study)

Koenigsmann M, Metz M, Ketzler S, Spohn C, Schulze M, Gerhardt A, Schick A, Johr C, Germing U

Abstract EXCALIBUR Jahrestagung DGHO Sept 28 – Oct 02 2018, Wien

Evidence for PTGER4, PSCA and MBOAT7 as risk genes for gastric cancer on the genome and transcriptome level.

Heinrichs SKM, Hess T, Becker J, Hamann L, Vashist YK, Butterbach K, Schmidt T, Alakus H, Krasniuk I, Höblinger A, Lingohr P, Ludwig M, Hagel AF, Schildberg CW, Veits L, Gyvyte U, Schüller V, Böhmer A, Schröder J, Gehlen J, Lordick F, Malfertheiner P, Möhler M, Pech O, Vassos N, Rodermann E, Izbicki JR, Kruschewski M, Ott K, Schumann RR, Vieth M, Mangold E, Kupcinkas L, Brenner H, Grimminger P, Bruns C, Gockel I, Nöthen MM, Lippert H, Ridwelski K, Lanas A, Keller G, Knapp M, Leja M, Kupcinkas J, Garcia-Gonzalez MA, Venerito M, Schumacher J

Carcinogenesis-Manuskript CAM4-2018-03-0711

<https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.1719>

Patient self reported WHO-ECOG-Score is frequently different to the assessment by oncologists.

Losem C, Dombrowsky J, Schulte C, Koenigsmann M, Frank-Gleich S, Musch R, Steinmetz T, MVZ Onkologie/Hämatologie Neuss, Tumorzentrum Niederrhein, GP Hämatologie/Onkologie Dortmund, SP Onkologie/Hämatologie/Immunologie Hannover, GP Onkologie/Hämatologie/Gastroenterologie Halle/Saale, Praxis Onkologie/Hämatologie Berlin, GP Onkologie/Hämatologie Köln

Abstract DKK 2018 – 20170824.odt

“Real-world” data on the use of ruxolitinib in myelofibrosis: 2018 interim analysis of the prospective, non-interventional study JAKoMo

Koschmieder S, Jacobasch L, Schulte C, Geer T, Brudler O, Wehmeyer J, Klausmann M, Gröschl B, Großer S, Pahl HL

Abstract Jahrestagung DGHO Sept 28 - Oct 02 2018, Wien

Patient self-reported performance-score (PPS) is feasible in the routine ambulatory setting and predictive for successful chemotherapy

Losem C, Dombrowsky J, Schulte C, Frank-Gleich S, Musch R, Steinmetz T

Abstract Jahrestagung DGHO Sept 28 – Oct 02 2018, Wien

Die Selbsteinschätzung des Performance-Status durch Patienten ist in der ambulanten Routineversorgung durchführbar und ermöglicht die Identifizierung von Patienten, die für eine Chemotherapie ungeeignet sind

Losem C, Dombrowsky J, Schulte C, Frank-Gleich S, Musch R, Steinmetz T

Poster Jahrestagung DGHO Sept 28 – Oct 02 2018, Wien

The need for transfusions in patients with lower risk myelodysplastic syndrome (MDS). Data from the regular care MDS-registry in Germany

Steinmetz HT, Toczek-Thiel J, Hellmich M, Aludin R, Lipke J, Liersch R, Sauer A, Tesch H, Heßling J, Schmitz S

Abstract Nr. A-0986-0016-00264 Jahrestagung DGHO Sept 28 – Oct 02 2018, Wien

Transfusionsbedarf von Patienten mit Niedrig-Risiko Myelodysplastischem Syndrom (MDS IPSS low + int-1) in der Regelversorgung. Daten aus dem MDS-Register der Niedergelassenen Hämatologen und Onkologen (NIHO-MDSRegister)

Steinmetz T, Toczek-Thiel J, Hellmich M, Aludin R, Lipke J, Liersch R, Sauer A, Tesch H, Heßling J, Schmitz S,

Poster P298 Jahrestagung DGHO Sept 28 – Oct 02 2018, Wien

Treatment of myeloproliferative neoplasia (MPN) in Germany. Data from the regular care MPN registry (NIHO-MPN-registry)

Steinmetz HT, Heinz M, Lipke J, Fries S, Sauer A, Uhlig J, Bürkle D, Nusch A, Schneider-Kappus W, Schmitz S

Abstract Nr. A-0986-0012-00272 Jahrestagung DGHO Sept 28 – Oct 02 2018, Wien

Poster P305 Jahrestagung DGHO Sept 28 – Oct 2 2018, Wien

Factors associated with the need for transfusions in patients with lower risk myelodysplastic syndrome (MDS). Data from the regular care MDS-registry in Germany

Steinmetz HT, Toczek-Thiel J, Hellmich M, Lipke J, Liersch R, Sauer A, Tesch H, Heßling J, Schmitz S

Abstract Nr 1155 EHA June 14 – June 17 2018, Stockholm

The prospective intersectoral national cohort study MYRIAM to study characteristics treatment and outcome of patients with multiple myeloma in Germany

Engelhardt, Knauf, Losem, Lipke, Kasper, Houet, Vannier, Jänicke, Marschner, Dechow, Einsele

Abstract EHA June 14 – June 17 2018, Stockholm

Treatment-free remission in real-world chronic myeloid leukemia patients: insights from German clinical hematology practices

Dengler J, Tesch H, Jentsch-Ullrich K, Gerhardt A, Schulte C, Lipke J, Löwe G, Holder IT, Kiani A

Abstract EHA June 14 – June 17 2018, Stockholm

2017

Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study.

Dörfel S, Steffens CC, Meyer D, Tesch H, Kruggel L, Frank M, Jänicke M, Marschner N, the TMK-Group (Tumour Registry Breast Cancer)

Breast Cancer Res Treat. Springer, Dec 2017, doi.org/10.1007/s12282-017-0823-7

Routine treatment and outcome of breast cancer in younger versus elderly patients: results from the SENORA project of the prospective German TMK cohort study.

Fietz T, Zahn MO, Köhler A, Engel E, Frank M, Kruggel L, Jänicke M, Marschner N, the TMK-Group (Tumour Registry Breast Cancer)

Breast Cancer Res Treat. Springer, Oct 2017 2017, doi.org/10.1007/s10549-017-4534-8

Behandlung von Patienten mit metastasierten kolorektalen Karzinomen (mKRK) in 1° und 2°line nach vorheriger molekularer Markeranalyse mittels NGS unter realen Versorgungsbedingungen in onkologischen Schwerpunktpraxen- Zwischenergebnisse des GO-KOLORAS-Registers-.

Lipp R, Freigang F, Eisen A, Brecht P, Tiemann M und die GO-KOLORAS Studiengruppe

Abstract P586. Jahrestagung DGHO Sept 30 – Oct 3 2017; Stuttgart

Molekulare Markeranalysen von Patienten mit metastasierten kolorektalen Karzinomen (mKRK) und nachfolgenden Therapieentscheidungen in 1° und 2°line unter realen Versorgungsbedingungen in onkologischen Praxen.

Lipp R, Freigang F, Eisen A, Brecht P, Tiemann M und die GO-KOLORAS-Studiengruppe

Abstract P585. Jahrestagung DGHO Sept 30 – Oct 3 2017, Stuttgart

Molekulare Testung, molekulare Veränderungen und Erstlinienbehandlung von Patienten mit Nicht-kleinzelligem Lungenkrebs (NSCLC) in Deutschland. Erste Ergebnisse der Klinischen Register Plattform CRISP (AIO-TRK-0315)

Griesinger F, Eberhardt WEE, Nusch A, Reiser M, Losem C, Ketzler-Henkel S, Zahn MO, Marschner N, Jaenicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, de Wit M, Metzenmacher M, Waller C, Kern J, Weichert W, Sebastian M, Thomas M

Abstract. Jahrestagung DGHO Sept 30 - Oct 3 2017, Stuttgart

Myeloproliferative Neoplasien (MPN) in der Regelversorgung: Erste Daten aus dem NIHO-MPN-Register.

Steinmetz HT, Heinz M, Lipke J, Sauer A, Fries S, Schneider-Kappus W, Uhlig J, Schmitz S

Abstract P549. Jahrestagung DGHO Sept 30 – Oct 3 2017, Stuttgart

Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer: results from the MaTox project.

Hurtz HJ, Tesch H, Göhler T, Hutzschenreuter U, Harde J, Kruggel L, Jänicke M, Marschner N, TMK-Group

Breast Cancer Res Treat. Springer, July 2017, doi: 10.1007/s10549-017-4365-7

Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the prospective German TMK cohort study.

Fietz T, Tesch H, Rauh J, Boller E, Kruggel L, Jänicke M, Marschner N, the TMK-Group (Tumour Registry Breast Cancer)

The Breast 2017; 34: 122-130

Results of the 5th interim analysis of the non-interventional MOMENT II-study: efficacy and safety of Nilotinib in newly diagnosed Ph+CML patients in chronic phase.

Tesch H, Lathan B, Sauer A, Tebbe S, Schulze M, Ulshöfer T, Lange E, Nusch A, Jäckle J, Janssen J, Rupprecht S, Meincke M, Tesanovic T

Abstract P538. Oncol Res Treat 2017; 40 (suppl3): 146

Myelodysplastic syndrome (MDS) in regular care in Germany – the oldest patients come to the fore.

Steinmetz HT, Germing U, Sauer A, Lathan B, Liersch R, Tesch H, Heßling J, Moorahrend E, Uhlig J, Reiser M, Wahdat R, Gattermann N, Totzke U, Schmitz S

Leukemia & Lymphoma 2017, <https://doi.org/10.1080/10428194.2017.1375105>

2016

Distribution of therapy regimen in patients with B-cell chronic lymphocytic leukemia (B-CLL) in 2015 in comparison to treatment strategies in 2012 based on real-world-evidence data of German oncological practices.

Feuerbach M, Freigang F, Schulte C, Hurtz H-J, Schwarzer A, Lipp R

Abstract P861. *Oncol Res Treat* 2016; 39 (suppl3): 258

A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC – a comparison of NGM and TCGA LUSC data.

Koleczko S, Schäpers C, Scheffler M, Ihle M, Kostenko A, Michels S, Fischer R, Nogova L, Serke M, Kaminsky B, Benedikter J, Brümmendorf TH, Ficker JH, Lorenz J, Schulte C, Schulze-Olden S, Brandes V, Abdulla D, Ueckerth F, Thurat M, Merkelbach-Bruse S, Büttner R, Wolf J

Abstract V134. *Oncol Res Treat* 2016; 39 (suppl3): 32

Treatment results of 13 years CML therapy in a private office. A contribution of the German CML Alliance.

Kämpfe D, Haverkamp T, Heil G, Schulte C, Tesch H, Stein H, Die Deutsche CML-Allianz

Abstract P215. *Oncol Res Treat* 2016; 39 (suppl3): 59

Cost analysis of patients with relapsed or refractory multiple myeloma (MM) based on real-world-evidence data of German oncological practices.

Feuerbach M, Freigang F, Schulte C, Hurtz H-J, Schwarzer A, Lipp R

Abstract P550. *Oncol Res Treat* 2016; 39 (suppl3): 164

Analysis of potentially targetable mutations in 1056 patients with squamous cell lung cancer undergoing routine NGS-based molecular diagnostics.

Koleczko S, Scheffler M, Steinhauser S, Kostenko A, Schäpers C, Michels S, Fischer R, Brandes V, Abdulla D, Nogova L, Ueckerth F, Thurat M, Serke M, Kaminsky B, Gerigk U, Benedikter J, Brümmendorf T, Ficker JH, Kruis W, Lorenz J, Schulte C, Schulze-Olden S, Merkelbach-Bruse S, Büttner R, Wolf J

Abstract P. 17th World Conference on Lung Cancer Dec 4-6 2016, Wien

Prognosis of myelodysplastic syndrome (MDS) in patients in the age of 80 years and older: Data from the Regular Care MDS Registry in Germany.

Steinmetz HT, Wahdat R, Haastert B, Sauer A, Lathan B, Lerchenmüller C, Tesch H, Germing U, Schmitz S

Blood 2016; 128:4333

Abstract P637. 58th Ann Meeting Am Soc Hem Dec 3-6 2016, San Diego, CA

Abstract P220. Jahrestagung DGHO Oct 14-16 2016, Leipzig

Mutation profiling and consecutive treatment decisions under knowledge of mutation results in patients with metastatic colorectal cancer (mCRC) in real world evidence (RWE) of oncological practices – first results of the GO-KOLORAS registry study.

Lipp R, Freigang F, Brecht P, Schwaner I, Steinmetz T, Schulte C, Tiemann M

Abstract P309. Oncol Res Treat 2016; 39 (suppl3): 97

Abstract: A-813-0024-00504. Jahrestagung der DGHO, OeGHO, SSMO, SSOM, SGMO und SGHSSH Oct 14-16 2016, Leipzig

Efficacy and safety of Nilotinib in newly diagnosed Ph+ CML patients in chronic phase: Results of the 4th interim analysis of the non-interventional MOMENT II-study.

Sauer A, Lathan B, Tebbe S, Ulshöfer T, Lange E, Schulze M, Nusch A, Janssen J, Losem C, Meincke M, Rupprecht S, Tesch H

Abstract P211. Oncol Res Treat 2016; 39 (suppl3): 52

Abstract P211. Jahrestagung DGHO Oct 14-16 2016, Leipzig

Three years after the start of enrolment: Current data from the prospective chronic lymphocytic leukemia (CLL)-registry of the German CLL Study Group.

Fink AM, Maurer C, Bahlo J, Kluth S, Linde H, Aldaoud A, Illmer T, Dengler J, Klausmann M, Lathan B, Al-Sawaf O, Fischer K, Wendtner CM, Eichhorst B, Hallek M

Abstract P855. Oncol Res Treat 2016; 39 (suppl3): 256

Abstract P. Jahrestagung DGHO Oct 14-16 2016, Leipzig

The relevance of the international prognostic scoring system (IPSS) for patients with myelodysplasia (MDS) at higher age.

Steinmetz HT, Wahdat R, Haastert B, Sauer A, Lathan B, Lerchenmüller C, Tesch H, Germing U, Schmitz S

Abstract P220. Oncol Res Treat 2016; 39 (suppl3): 61

Abstract P. Jahrestagung DGHO Oct 14-16 2016, Leipzig

Clinical characteristics and long-term outcome of myeloid/lymphoid neoplasms with PDGFRB fusion genes in chronic or blast phase.

Jawhar M, Naumann N, Schwaab J, Dietz C, Casper J, Dang TA, Dietze L, Döhner K, Hänel A, Lathan B, Link H, Lofti S, Lubert V, Maywald O, Müller L, Platzbecker U, Prümmer O, Thomssen H, Töpelt K, Schmitt K, Baurmann H, Vieler T, Hofmann WK, Haferlach C, Cross NCP, Fabarius A, Reiter A, Metzgeroth G

Abstract P. 21st Congress Eur Hem Ass June 9-12 2016, Copenhagen

Age distribution of patients with myelodysplastic syndrome (MDS) in Germany and their prognosis according to the international prognostic scoring system (IPSS): Data from the regular care MDS registry.

Steinmetz HT, Böttger I, Wahdat R, Haastert B, Sauer A, Lathan B, Germing U, Schmitz S

Abstract P. 21st Congress Eur Hem Ass June 9-12 2016, Copenhagen

Mehr Eisen als uns gut tut – Expertenbericht: Bei der Hämochromatose ist eine unspezifische Leberwerterhöhung wichtig für die Differenzialdiagnose.

Golka K, Collette D, Claus M, Niedner H, Butzeck B

Ärztewoche 28. April 2016, SpringerMedizin, Springer Verlag Heidelberg

CONIFER – Non-interventional study to evaluate therapy monitoring during Deferasirox treatment of iron toxicity in MDS patients with transfusional iron overload in the course of treatment.

Tesch H, Bruch HR, Dencausse Y, Heßling J, Lerchenmüller C, Michel G, Schlag R, Skorupa A, Schneider-Schranz C, Wolf S, Schulte C

DOI 10.1159/000447035

Oncol Res Treat 2016, 39 (7-8): 424-431

Abstract. 32. Deutscher Krebskongress Feb 24-27 2016, Berlin

Efficacy and safety of Nilotinib in routine clinical management of newly diagnosed Ph+ CML patients in chronic phase – 3rd interim analysis of the non-interventional MOMENT II-study.

Lathan B, Sauer A, Ulshöfer T, Lange E, Tebbe S, Schulze M, Janssen J, Meincke M, Frank O, Tesch H

Abstract P114. Deutscher Krebskongress Feb 24-27 2016, Berlin

Hämochromatose – Wichtige Differentialdiagnose der unspezifischen Leberwerterhöhung. CME Zertifizierte Fortbildung.

Golka K, Collette D, Claus M, Niedner H, Butzeck B

DOI 10.1007/s40664-016-0101-0

Zbl Arbeitsmed 2016/3; 66: 171-180

Monitoring of deferasirox treatment in patients with transfusion-dependent iron toxicity due to myelodysplastic syndromes.

Tesch H, Schulte C, Bruch HR, Dencausse Y

Poster. Centrum für Hämatologie und Onkologie Bethanien 2016, Frankfurt

2015

Ergebnisse einer Interimsanalyse der nicht-interventionellen MOMENT II-Studie zur Erfassung von Wirksamkeit und Sicherheit von Nilotinib bei neu diagnostizierten Ph+ CML-Patienten in chronischer Phase im klinischen Alltag.

Lathan B, Sauer A, Ulshöfer T, Lange E, Tebbe S, Schulze M, Janssen J, Meincke M, Frank O, Tesch H
Abstract P456. Jahrestagung DGHO Oct 9-13 2015 Berlin

Assessment of the myelodysplasia (MDS) international prognostic scoring system (IPSS) in routine care: Data from the regular care MDS registry.

Steinmetz TH, Böttger I, Sauer A, Lathan B, Germing U, Schmitz S
Abstract V606. Jahrestagung DGHO Oct 9-13 2015 Berlin

2014

Interim Results of a Phase 2 Study of MEDI-551 and Bendamustine vs. Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Gladstone DE, André M, Zaucha JM, Assouline S, Bellam N, Cascavilla N, Jourdan E, Panwalkar A, Patti C, Schulte C, Zaja F, Goswami T, Elgeioushi N, Streicher K, Bao H, Spaner D

Abstract P4472. 56th Ann Meeting Am Soc Hem Dec 6-9 2014, San Francisco, CA

Phase 2 Open-Label Study of MEDI 551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL.

Gladstone DE, André M, Zaucha JM, Araujo C, Assouline S, Bellam N, Cascavilla N, Jourdan E, Panwalkar A, Patti C, Schulte C, Zaja F, Goswami T, Elgeioushi N, Spaner D

Abstract 3028. J Clin Oncol 2014; 32 (suppl 5)

Results of an interim analysis of the non-interventional MOMENT II-study for determining efficacy and safety of Nilotinib in newly diagnosed Ph+ CML patients in chronic phase.

Lathan B, Sauer A, Titgemeyer J, Groschek M, Gabrysiak T, Hutzenreuter U, Tebbe S, Meincke M, Frank O, Tesch H

Abstract P215. Oncol Res Treat 2014; 37 (suppl 5): 63

Hämochromatose – eine wichtige, selten gestellte Differentialdiagnose auch in der Arbeitsmedizin.

Golka K, Collette D, Müller JF, Claus M, Niedner H, Butzeck B

Umweltmed – Hygiene – Arbeitsmed 19 (2) 2014

Abstract P. Betriebl. Gesundheitsförderung/2. 54. Wiss. Jahrestagung der DGAUM April 2-4 2014, Dresden

Need of transfusion, treatment and survival of patients with Myelodysplastic Syndromes (MDS): Update of the outpatient MDS registry.

Steinmetz TH, Böttger I, Lathan B, Sauer A, Severin K, Germing U, Schmitz S

Abstract V. Jahrestagung DGHO Oct 10-14 2014 Hamburg

2013

Efficacy and safety of Nilotinib in routine clinical management of newly diagnosed Ph+ CML patients in chronic phase – interim analysis of the non-interventional MOMENT II study.

Lathan B, Sauer A, Titgemeyer J, Groschek M, Gabrysiak T, Hutzenreuter U, Tebbe S, Meincke M, Frank O, Tesch H

Abstract P217. Onkologie 2013; 36 (suppl 7): 62